A new review published on Aug. 3 explores how recent advances in understanding X chromosome inactivation are opening potential therapeutic opportunities for a range of X-linked genetic disorders, including Rett syndrome, Fabry disease, Duchenne muscular dystrophy, and hemophilia.
The article details the molecular mechanisms that govern X chromosome silencing. It explains that during early embryonic development in female mammals, one of the two X chromosomes is randomly silenced in each cell through a process controlled primarily by the long non-coding RNA known as XIST. This molecule recruits epigenetic regulators to compact chromatin and suppress gene expression on the inactive chromosome.
The review reports that this process is not always perfectly balanced. Some individuals experience skewed X chromosome inactivation (XCI), where one chromosome is preferentially silenced across more cells than the other. This skewing can significantly affect disease severity among women who carry mutations in genes located on the X chromosome. For example, patients with Rett syndrome—a neurodevelopmental disorder caused by mutations in MECP2—may have milder symptoms if their mutant allele is preferentially silenced, or more severe symptoms if their normal allele is inactive.
Similar influences of skewed XCI have been observed or suggested for other conditions such as Fabry disease, Becker muscular dystrophy, hemophilia, and several additional disorders linked to genes on the X chromosome. The article also describes emerging laboratory techniques for measuring patterns of XCI with increasing accuracy—including HUMARA assays, bisulfite sequencing methods, RNA-based analyses, and newer nanopore sequencing approaches combining CRISPR-Cas9 enrichment with direct methylation assessment—which may help identify patients most likely to benefit from targeted therapies.
A major focus of current research involves experimental strategies aimed at reactivating beneficial genes on the inactive X chromosome. The review discusses efforts to inhibit regulators such as ACVR1 and PDPK1—key factors influencing both chromatin structure and expression of non-coding RNAs like XIST—in order to restore activity from healthy gene copies present but normally silent in affected individuals.
